SCHEMBL30837878

SCHEMBL30837878

COCC1CCN(c2cc(N3CCC(O)CC3)ncn2)CC1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ LRRK2 Q5S007 2/20 0.40
▸ PIK3CA P42336 1/20 0.39
▸ MTOR P42345 1/20 0.39
▸ CYP2C19 P33261 1/20 0.38
▸ SMO Q99835 1/20 0.38
▸ HRH4 Q9H3N8 2/20 0.38
▸ CHEK1 O14757 2/20 0.38
▸ CHEK2 O96017 2/20 0.38
▸ MAP4K4 O95819 1/20 0.38
▸ PDPK1 O15530 1/20 0.38
▸ GPR119 Q8TDV5 1/20 0.37
▸ FFAR2 O15552 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ ITGB2 P05107 1/20 0.36
▸ ICAM1 P05362 1/20 0.36
▸ ITGAL P20701 1/20 0.36
▸ ENPP1 P22413 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11981591 0.79 SMO (0.46) LRRK2PIK3CAMTORCYP2C19SMO
SCHEMBL14163270 0.72 SMO (0.46) LRRK2SMOHRH4CHEK1CHEK2
SCHEMBL23024919 0.72 RIPK1 (0.46) LRRK2SMOCHEK1CHEK2PDPK1
SCHEMBL11960320 0.72 LRRK2 (0.45) LRRK2CYP2C19SMOHRH4GPR119
SCHEMBL12296242 0.70 DPP4 (0.44) LRRK2PIK3CAMTORSMOHRH4
SCHEMBL14872323 0.70 DPP4 (0.44) LRRK2PIK3CAMTORSMOHRH4
SCHEMBL14872316 0.70 DPP4 (0.44) LRRK2PIK3CAMTORSMOHRH4
SCHEMBL792754 0.70 SORD (0.45) HRH4GPR119LMNA
SCHEMBL13472382 0.69 KMO (0.66) LRRK2SMOLMNAHTT
SCHEMBL10569035 0.69 MAP4K4 (0.46) MAP4K4GPR119LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4572765-A1 USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE Mitodicure GmbH (DE) 2025-06-25 — — EP disclosed
WO-2024038089-A1 USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE MITODICURE GMBH (DE) 2024-02-22 — — WO disclosed
Send feedback